Brind.

MAIA Biotechnology Gains Regulatory Approval for Pivotal Clinical Trials in Spain and…

1 report, 1 independent Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

MAIA Biotechnology, Inc. announced on September 23, 2026, that it received regulatory approval to screen patients for its pivotal Phase 3 THIO-104 clinical trial in two countries. The company gained approval from the Spanish Agency for Medicines and Medical Devices (AEMPS) and Portugal’s National Authority of Medicines and Health Products (INFARMED). These approvals allow the company to conduct the trial in Spain and Portugal for non-small cell lung cancer (NSCLC) patients.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The expansion of the pivotal Phase 3 trial into Spain and Portugal adds important European markets to the research program. The company stated that clinical trial participation offers patients access to investigational therapies in markets where access to newly approved lung cancer treatments has historically lagged.

From manilatimes.net

Who's involved

  • SpainGranted regulatory approval by AEMPS to begin screening patients for the pivotal Phase 3 clinical trial of THIO-104.
  • PortugalGranted regulatory approval by INFARMED to begin screening patients for the pivotal Phase 3 clinical trial of THIO-104.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped